Navigating the CMS 14-Day Rule in Biomarker Testing

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

November 10, 2012

PMO Interview with the Innovator Series: Volume 3

Kim Popovits, Chairman, CEO and President, Genomic Health Inc., offers a definition of personal medicine in the first segment of this new video from Personalized Medicine in Oncology.

January 13, 2015

Benefits of Breast Cancer Index

Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer IndexSM (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.